Following a week of round-the-clock deliberations, the World Trade Organization (WTO) this morning announced a deal on waiver of IP rights for COVID-19 vaccine technologies under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The final text has made almost no one happy and largely mirrors the draft text going into negotiations, with a few key changes. With respect to open questions in the draft text, the final agreement indicates that all developing country WTO Members will be considered eligible to take advantage of the waiver, but that those with “existing capacity to manufacture COVID-19 vaccines are encouraged to make a binding commitment not to avail themselves of this Decision.” This language is primarily targeted at China, which has publicly stated that it would not use the waiver provision but had objected to language based on percentage of global vaccine exports that would have categorically excluded it. The draft text had encouraged members with vaccine export capabilities to opt out rather than to make a binding commitment.
Recent Posts
- Tariffs, Tech Wars, and Patent Turmoil: Navigating IP Strategy in a Rapidly Changing World | IPWatchdog Unleashed
- Life Sciences Masters Panelists Lament Mounting Policy Uncertainty
- Interveners Left Out in the Cold: EPO’s G 2/24 Tightens Rules for Late Parties to Patent Challenges
- Massie to Reintroduce RALIA in Bid to Abolish PTAB
- Reddit Dubs Perplexity AI and Data Scraping Companies ‘Would-Be Bank Robbers’
